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End Pointsfor Biomonitoring:
Assay Sensitivity/Selectivity
Charles S. Aaron, David M. Zimmer,
Philip R. Harbach, and Roger L. Yu
The Upjohn Company, Kalamazoo, Michigan
Estimation of population exposure and biological impact of potential hazards are central reasons
for performing biomonitoring. The sensitivity of the biomonitoring methods and the linkage of the
measured phenomenon to human disease are also important, but often overlooked, considera-
tions. We are conducting experiments to evaluate the sensitivity of hprt mutation measurement
in the nonhuman primate, the cynomolgus monkey. Ourfindings demonstrate in the monkey that
hypoxanthine guanine phosphoribosyltransferase (hprt) mutations produced in vivo can be
detected using techniques originally worked out using human cells; cynomolgus monkeys were
chosen to avoid many of the complications encountered in studying humans. Sequencing of
mutants from the monkey using reverse transcriptase polymerase chain reaction methods has
led us to conclude that there is similarity of the spectra observed between the spontaneous
mutations detected in the two species. However, more recent data suggest that due to low
sensitivity, the method is probably not appropriate for routine biomonitoring of randomly selected
populations. For example, the inability of the hprt mutation assay to detect some very potent
mutagens in the monkey and the effects of the time-dependent pattern of mutant occurrence
serve to urge caution in interpretation of elevation or lack of elevation in mutant frequency.
Mechanisms for splitting and archiving samples of human tissues/blood from populations at risk
may prove valuable as methods improve. Environ Health Perspect 104(Suppl 3):521-525 (1996)
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Introduction
In the area ofgenetic toxicology, the direct
link between genotoxins and human dis-
ease has been elusive (1). This is true for
most human cancer as well as for heritable
effects (2). The resulting approach has
therefore been to select surrogate markers
that respond to known genotoxic influ-
ences in laboratory animals and tissue cul-
ture and to use these surrogates to estimate
the human exposure to genotoxins. The
most comprehensive paradigm for extrapo-
lation ofthis laboratory data to the human
condition, the parallelogram approach
(3,4), depends on perceived links between
the surrogate markers and genetic ill
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health. Long ago the use of cytogenetic
damage was established as a suitable surro-
gate dosimeter (5) for estimation ofexpo-
sure to ionizing radiation; however, many
chemicals do not efficiently induce chro-
mosomal damage observable in the micro-
scope. Faced with this challenge, other
methods are proposed (see Table 1) for use
in biomonitoring when genotoxic hazards
are suspected. In particular, methods have
been proposed and used for monitoring of
workers (6) and other populations (19),
based on screening for gene mutations such
as the absence ofhprtgene activity in lym-
phocytes. We will discuss some ofour data
which suggests that adoption ofthese meth-
ods may give a sense offalse security and
should therefore beapproached cautiously.
In large measure, reliance on human
epidemiology to supply the evidence of
linkage between genetic disease (or cancer)
and exposure to risk factors suffers from
the intrinsic insensitivity ofthe methods
and the amount of time that must tran-
spire between exposure and end point.
Molecular epidemiology (19), i.e., use of
molecular surrogates of exposure such as
mutant frequencies or DNA adduct levels,
may represent improvements in the meth-
odology and decrease the time for carrying
out such studies. Discovery ofa probable
linkage between hazard and end point
(often using data from animal studies)
results in public health efforts to reduce the
exposure ofthe affected population. Such
discovery processes are particularly com-
promised in human populations because
significant portions ofthe population par-
ticipate in activities that are known to have
some component ofgenotoxic potential,
i.e., smoking, sunbathing, etc.
Several years ago we began a series of
studies designed to determine whether the
hprt method might provide a suitable sur-
rogate marker for in vivogenotoxic activity.
These studies suggest that the low sensitiv-
ity observed in the peripheral lymphocytes
ofthe cynomolgus monkey, i.e., inability
to detect genotoxic activity of known
potent mutagens, complicates the interpre-
tation ofnegative results. Some practical
aspects ofthe deployment ofavailable gene
mutation biomarkers for human monitor-




All chemicals were reagent grade. Ethylni-
trosourea (ENU) was obtained from Pfaltz
and Bauer, Inc., Waterbury, CT. Cydophos-
phamide (CP) was obtained from Sigma
Chemical Co., St. Louis, MO. Ethylmeth-
anesulfonate (EMS) was obtained from the
Eastman Kodak Company, Rochester, NY.
Chloroethylmethanesulfonate (Cl-EMS)
was obtained from Aldrich Chemical Co.,
Milwaukee, WI. Adozelesin (U-73975)
and CC-1065 were manufactured by The
Upjohn Company, Kalamazoo, MI.
Isolation ofMutants from the
Cynomolgus Monkey
The methods for isolation and cloning of
the hprt mutations from the (wild caught)
Table 1. Candidate methods for biomonitoring.
Method References
Chromosome aberrations (6-9)
Sister chromatid exchanges (10,11)
Protein adducts, 32P-postlabeling (12)
Concurrent multiple end points (6,13,14)
DNA repair enzymes (1,15)
Gene mutation (6,9,16-18)
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cynomolgus monkey are described else-
where (20). Blood samples were collected
weekly or at somewhat more separated
intervals over the course of the studies
described here.
DNASequencing
Detailed information concerning the deter-
mination ofDNA sequence using conven-
tional methods is described elsewhere
(21,22).
Dosing
Doses were administered either by intra-
peritoneal injection or by intravenous infu-
sion. ENU (77 mg/kg), EMS (300 mg/kg),
and CI-EMS (35-50 mg/kg) were admin-
istered by intraperitoneal injection. CC-
1065 (6 pg/M2), adozelesin (6 pg/M2), and
cyclophosphamide (75 mg/kg) were
administered intravenously.
Results
The spontaneous frequency ofmutations at
the hprtlocus in the cynomolgus monkey
is similar to that observed in the human, in
the rat, and in the mouse (Table 2) (16,20).
Following treatment ofthe monkey with
ENU, the mutant frequency increases
significantly in a time-dependent fashion,
reaching levels as high as a 35-fold increase
over the pretest spontaneous frequency
during a period of80 days. A reproducible
reduction or falloff in mutant frequency
follows the peak; however, in repeated
experiments the mutant frequencydoes not
decrease to the levels of mutant incidence
established prior to exposure. The induced
mutant fraction stabilizes (Table 3); this
elevated plateau level has been observed
even several years after exposure to ENU.
Sequencing of mutants at long periods
after exposure reveals them to be predomi-
nantly ofindependent origin and typical of
an ENU-induced mutation spectrum (21).
Sequencing of a large group ofspontane-
ously occurring mutations (22) suggests
similarity of the spectrum of observable
mutations to that ofhumans. Therefore
the experiments described here were carried
Table 2. Comparison of representative spontaneous
mutation frequency data for the cynomolgus monkey,




Rat 1-3x10 6 (24,25)
Cynomolgus monkey 1-3x10 (20)
Human 5x104 (16)
out to evaluate the capability ofthe in vivo
hprtmutation assay to reflect exposure to a
variety ofmutagens (Table 4). No evidence
ofinduction ofmutations was seen follow-
ing single dose exposure to high levels of
EMS (a direct acting ethylating agent),
cyclophosphamide (a mutagen that requires
metabolic activation), Cl-EMS (a potent
cross-linking agent), or adozelesin [pro-
duces a large adduct in the minor groove of
the DNA (1,26)] or its parent compound
CC-1065. While the experiment with
cyclophosphamide was limited in extent
(data from a single animal), strong evi-
dence ofmutation induction was not seen.
The only suggestion ofmutation induction
(2-fold increase), i.e., elevation ofthe cal-
culated frequency ofmutants, occurred at
very low cloning efficiencies; the variability
in cloning efficiency significantly affects
the calculated mutation frequency. All
other compounds listed except ENU were
more extensively tested than CP without
observed induction ofmutation.
In addition to single-dose experiments
with ENU, we carried out two kinds of
ENU split-dose experiments. In the first
experiment (Table 4), we treated monkeys
with ENU a second time more than 2 years
after the initial dose. This interval was cho-
sen to ensure that the mutant fraction had
achieved stabilization following the first
dose. The second experiment (Table 4) was
carried out by the more traditional split-
dose regimen, namely, giving five equally
spaced doses with the total equivalent to
the initial dose (77 mg/kg) used to induce
mutations. The result (Tables 4 and 5) of
readministration of ENU after 830 days
was a repeat ofthe earlier observed muta-
tion induction kinetics, namely, a rise in
mutation frequency to a peak at about 80
days after treatment and a slow but steady
decrease in mutation for the next 3 to 4
months until a new, higher plateau was
reached at about double the plateau level
after the first exposure. This result strongly
suggests additivity ofthe effect ofmultiple
doses of ENU. In the second experiment,
in which five daily doses were administered
(each dose was 1/5 the initial dose in the
single dose experiment), the data also
supports a simple additivity ofdose (Table
5). The mutants we have sequenced are
consistent with the expectation from the
ENU spectrum.
Table 3. Mean mutation frequencies observed in cynomolgus monkeyT lymphocytes treated twicewith ENU (77/kg).
Time afterfirst Mean mutation Number of Number of observations
Regimen treatment (days) frequency animals (each animal)
Firsttreatment -160 to 830 20-25x10 2 16
Second treatment -1806-2163 40x10.6 2 6
The mean mutation frequency is the arithmetic mean calculated based on all observations made during the time
after first treatment. These monkeys were treated at day zero and again at approximately day 830. Not shown are
the peak mutation frequencies that occurred at approximately 80 days after each treatment (see Table 5). The
pretest mean spontaneous frequencies observed in these two monkeys were 1.7 and 6.3 x 10-6 respectively. Note
the time interval is given relative to thefirsttreatment in both lines ofthe table.
Table 4. Compounds evaluated forthe induction ofmutations in the Tlymphocytes ofcynomolgus monkeys.
Number of
Compound Dose Type agent animals Result
Ethylnitrosourea 77 mg/kg Ethylating 6 Positive
Cyclophosphamide 75 mg/kg Metabolically activated 1 Likely negative
CC-1065 6 pg/M2 Bulky DNAadduct 3 Negative
Adozelesin 6pg/M2 Bulky DNAadduct 5 Negative
Ethylmethanesulfonate 300 mg/kg Ethylating 2 Negative
CI-ethylmethanesulfonate 35-50 mg/kg Crosslinker 3 Negative
Table 5. Comparison of hprt mutation frequencies observed in cynomolgus monkey peripheral T lymphocytes
following multiple doses ofethyinitrosourea.
Regimen/treatment number Dose Peak mutationfrequency(104) Number ofanimals
Single treatment 77 mg/kg 33-77.9 4
Second treatment 77 mg/kg 159-190 2
Five dailydoses 15.4mg/kg/day 24-33 2
Spontaneous mutantfrequency ofall animals(33 animals and 103 determinations) in ourcolony is 2.9±2.9x104.
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Discussion
Biomonitoring is carried out to assess
whether individuals or populations have
been exposed to toxicants. The application
of biological indicators of exposure is
frequently viewed as more relevant than
purely chemical or physical measures
because biomonitoring provides an impres-
sion of the likely effects on man to be
expected from exposure. The avoidance of
mutational disease (1) is the end goal of
the activity. There are techniques that
might be appropriate for monitoring for
evidence ofexposure to mutagenic hazards.
Perera and Whyatt (19) have reviewed the
available biomarkers and their uses in mol-
ecular epidemiology; these authors point
out that validation of the available bio-
markers is still needed. As part ofthe vali-
dation described by Perera and Whyatt
(19), there is a need to obtain confirma-
tion ofthe assay results by other methods.
Essentially the results in this paper consti-
tute part ofthe kind ofvalidation needed
to understand the limitation of the hprt
gene mutation assay, which was originally
developed using human cells.
Cynomolgus Monkey
hprtMutation Induction
We have shown (20) that measurement of
mutation frequencies, as well as sequencing
of the mutants (22), at the hprt locus in
the cynomolgus monkey is feasible using
the techniques developed for use with
human cells. We have also shown (21) the
ability to detect increases in mutant fre-
quency following exposure to ENU, a very
potent mutagen. However, several features
of the time course of occurrence of the
increase in mutant frequency were unex-
pected. For example, the peak in mutant
yield is seen only at approximately 80 days
following treatment, with a gradual
increase slowly occurring before this time.
This is surprising with a direct acting alky-
lating agent such as ENU because the dam-
age occurs very rapidly; thus, lymphocytes
that are stimulated to divide shortly after
treatment should experience mutagenesis as
they pass through S-phase. The lag before
mutation is observed could be due to muta-
tion in a stem cell population, but this
speculation is far from proven; however,
sequencing of mutants detected at long
periods after treatment fails to confirm
clonal origin of these mutants (Harbach
and Aaron, unpublished data). The second
feature of the time course experiments,
which is somewhat difficult to reconcile
with the expectation ofclonality, is that
after approximately 150 days the observed
mutant frequency stabilizes (Table 3) at an
elevated level compared to predose levels.
This observation raises the question about
whether observed mutation frequency
increases can be used to establish the
source of mutagenic insult in a randomly
selected population.
The induction of mutations in cyno-
molgus monkey T lymphocytes was not
observed using compounds (Table 2) that
are representative ofseveral types ofagents
including CP, EMS, Cl-EMS, CC-1065,
and adozelesin. Ofthese compounds, the
result with adozelesin is the most disturb-
ing because this is the most mutagenic
compound tested in this laboratory in a
variety ofstandard genetic toxicology tests.
Adozelesin has been tested in assays for
gene mutation (CHO/HPRTas well as
AS52/gpt) and chromosomal aberration
assays (27,28) and has systematically been
observed to be a particularly potent muta-
gen and clastogen. Adozelesin (26) reacts
directly with DNA and does not require
metabolic activation. Interestingly, the
binding is due to alkylation via ring open-
ing ofa cyclopropyl group and the binding
appears to be reversible (29), one ofvery
few examples of such an alkylation or
reversible alkylation. Furthermore, several
lines ofevidence reveal the capability ofthe
compound and others ofthe class to pro-
duce mutations at the site ofthe consensus
binding domain in DNA (the binding tar-
get is a run offive A residues [AAAAA] or
an ATT site). Consistent with this expecta-
tion, the only strain ofthe standard Ames
tester set that is positive under the influence
ofthis drug is TA102 (unpublished data),
the only strain in the Ames tester set to
contain an ATT genetic target for mutage-
nesis. Also, the spectrum of mutations
recovered in the AS52/gpt gene is exactly
what would be predicted from the known
locations ofputative binding sites (Tindall
and Aaron, unpublished data). The doses
at which mutagenesis is detected are
extremely low in both TA102 and AS52.
In the in vivo experiments with monkeys at
doses that give complex chromosomal
aberrations in approximately 32% of the
lymphocytes (data not shown), we could
find no evidence ofgene mutagenesis at
hprt up to 6 months after exposure. The
failure to detect mutant frequency increases
with this diverse array ofcompounds even
at very high (toxic) doses suggests that the
assay is particularly insensitive to many
mutagens. The logical conclusion that fol-
lows from these observations is that there is
a significant likelihood of false negative
results, i.e., one would be very likely to
incorrectly conclude that no exposure had
taken place even though very significant
exposure could have occurred. Further-
more, we found little evidence in our stud-
ies using monkeys that techniques such as
use of mutational spectra as a means of
fingerprinting the compound and retro-
spectively identifying the toxicant would
prove feasible. However, the spectra ofthe
spontaneous mutants analyzed to date (22)
suggest good agreement between the types
of mutants currently seen in cynomolgus
monkeyand human hprtdatabases.
Conclusions
One concern about the available methods
for detecting mutagen exposure through
use of biomonitoring is the lack of sen-
sitivity of the hprt gene mutation assay.
Methods such as multiplex PCR-based
techniques could provide methods for
addressing this concern. In addition, the ad
hoc nature ofthe current process for obtain-
ing and processing samples needs to be
revamped. Our data from experiments with
the cynomolgus monkey indicate that
mutation frequency measurements require
great care in interpretation, even when data
are gathered under the controlled laboratory
conditions established for these primates.
In the field, i.e., at the sites ofacciden-
tal or other exposures, these methods for
sample procurement need to be very care-
fully worked out and the strength ofthe
overall protocols needs to be further vali-
dated and improved. A more systematic
approach to the collection and handling of
samples is important. Perhaps a central
international repository for collection and
storage of biological samples might be
established with the aid ofan international
organization. Such a repository should
ensure timely sample acquisition following
an accident, as well as ensure appropriate
storage and sample integrity. Recently, data
have been published showing that the
profile oflymphocyte subpopulations is
not affected by storing frozen cells for
periods up to 8 days (30) or by stimulation
ofGo lymphocytes (31). Such a repository
approach would be similar to approaches
used for monitoring human diseases. The
advantage of the repository approach is
obvious, namely, a more systematic and
thorough evaluation ofsamples could be
planned. In addition, stored samples in a
repository could be analyzed retrospectively
when either better techniques become
available or greater insight leads to more
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informative questions. Such a system
ought to offer the opportunity to carry out
the necessary technology transfer to labo-
ratories in less developed areas so that local
laboratories could be trained to do the
evaluation and interpretation.
When evidence ofexposure is detected,
appropriate public health steps should be
taken to protect the individuals (3,4,7,8);
lack ofevidence ofexposure is usually not
accompanied by any necessarypublic health
measures. However, the state ofthe art for
biomonitoring with respect to identifying
mutagen exposure is relatively new com-
pared to that for infectious diseases, for
example, and thus the assays available are
in varying states ofvalidation (19). Some
serious drawbacks, i.e., low sensitivity (32),
to the widespread deployment ofthe avail-
able tools of biomonitoring are apparent.
Furthermore, the availability ofequipment
and technical skill is limited in many parts
ofthe world where biomonitoring must be
practiced. Systematic collection and archiv-
ing ofsome ofthese samples would provide
biological material that could significantly
contribute to the retrospective identification
ofcausative factors.
Our interest in the mechanisms of in
vivo mutagenesis has led us to evaluate the
induction of hprt mutations as well as a
large number ofother kinds ofmutations.
In those experiments, the question ofsensi-
tivity has often come up. In the case of
hprt in the monkey, the series of experi-
ments described here leads us to urge cau-
tion in too heavy reliance on single end
point methods, particularly the hprtassay,
as the basis ofdecision making. In the con-
text ofthese findings, it is pertinent to ask
"What question does biomonitoring
address?" Conferences such as this provide
a forum for addressing this question.
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